): The proposed Research Training Program is intended to equip physicians and Ph.D. scientists at the postdoctoral level for independent research-oriented careers in the field of oncology. The program is based on the research interests and expertise of 21 funded faculty members in the Division of Hematology/Oncology of the Department of Internal Medicine and the Comprehensive Cancer Center of the University of Michigan (which includes faculty with appointments in other clinical and basic science departments). General areas of research focus include (1) the molecular genetic basis of neoplastic transformation, (2) the dis-regulation of programmed cell death in malignancy, (3) the development of novel immunologic approaches to the treatment of cancer, (4) the cellular mechanisms that control tumor cell invasion and metastases, and (5) the development of novel pharmacologic strategies to prevent malignant transformation or to treat established tumors. Trainees selected for this program will spend 2-3 years in the laboratory or relevant clinical research environment under the direct supervision of a training program faculty mentor and will develop skills in (1) identifying testable hypotheses that address important questions in oncology research, (2) acquiring the necessary technical expertise to test the hypotheses identified, (3) critically evaluating the data generated, and (4) developing the necessary skills o written and oral communication to promulgate the conclusions made. The majority of the trainees will have an M.D. degree, 3 years of House Officer training in Internal Medicine, and a year of clinical sub- specialty training in Medical Oncology/Hematology. M.D. trainees with limited prior research experience will be encouraged to participate in an intensive 3 month Post-Doctoral Research Training Program to introduce them to important concepts in cellular and molecular biology. A minority of trainees will have Ph.D.s in relevant biological sciences with an interest in pursuing oncology-related research. During their research training experience, trainees are expected to attend relevant research seminars offered by the Division and Cancer Center and to present the results of their investigative efforts in laboratory meetings and research conferences. Trainees are expected to apply for individual extramural research support, and to author research reports and abstracts for publication and presentation. The progress of trainees will be monitored continuously by their research mentors and yearly by the Program Director. Upon the completion of the post-doctoral training period, trainees should be prepared to pursue independent academic careers in oncology.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Internal Medicine/Medicine
Schools of Medicine
Ann Arbor
United States
Zip Code
Qin, Angel; Street, Lindsay; Cease, Kemp et al. (2017) Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 18:559-564
Qin, Angel; Gadgeel, Shirish (2017) The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. Target Oncol 12:709-718
Decker, A M; Cackowski, F C; Jung, Y et al. (2017) Biochemical Changes in the Niche Following Tumor Cell Invasion. J Cell Biochem 118:1956-1964
Cackowski, Frank C; Eber, Matthew R; Rhee, James et al. (2017) Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy. J Cell Biochem 118:891-902
Qin, Angel; Kalemkerian, Gregory P (2016) Cisplatin, Etoposide, and Irinotecan for Relapsed Small-Cell Lung Cancer. Transl Cancer Res 5:S1142-S1144
Qin, Angel; Ramnath, Nithya (2016) The ""liquid biopsy"" in non-small cell lung cancer - not quite ready for prime time use. Transl Cancer Res 5:S632-S635
Qin, Angel; Coffey, David G; Warren, Edus H et al. (2016) Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med 5:2567-78
Yumoto, Kenji; Eber, Matthew R; Wang, Jingcheng et al. (2016) Axl is required for TGF-?2-induced dormancy of prostate cancer cells in the bone marrow. Sci Rep 6:36520
Wood, Sherri; Feng, Jiane; Chung, Jooho et al. (2015) Transient blockade of delta-like Notch ligands prevents allograft rejection mediated by cellular and humoral mechanisms in a mouse model of heart transplantation. J Immunol 194:2899-908
Yang, Huibin; Palmbos, Phillip L; Wang, Lidong et al. (2015) ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase. J Biol Chem 290:27146-57

Showing the most recent 10 out of 36 publications